Manuel Irimia
banner
mirimiam.bsky.social
Manuel Irimia
@mirimiam.bsky.social
ICREA Evolutionary Biologist working on transcriptomics of development and evolution at @upf.edu and @crg.eu. Coordinator of the @evomg-bcn.bsky.social Joint Program.

Lab website: http://transdevolab.com
Reposted by Manuel Irimia
With these positions, you can join:
🔸 The Molecular Virology Laboratory (@viroupf.bsky.social) led by Juana Diez 🦠😷🤧

🔸 The Developmental and Evolutionary Transcriptomics Laboratory led by Manuel Irimia (@mirimiam.bsky.social) - @crg.eu 🧬🐟🐭

cc @evomg-dn.bsky.social
#PhDOffer #AcademicJobs
October 20, 2025 at 7:35 AM
Reposted by Manuel Irimia
At the @melisupf.bsky.social, @mirimiam.bsky.social would like to recruit two fully-funded #PhDcandidate for the #MSCA Doctoral Network @evomg-dn.bsky.social.

#AcademicSky #ResearchJobs
October 15, 2025 at 11:09 AM
The second project will investigate the evolution of bat pancreases at the single-cell level to identify transcriptomic adaptations to dietary shifts. The ultimate goal is to find genomic changes that could shed light into type 2 diabetes risk in humans.

www.evomg-dn.eu/project/mole...
October 15, 2025 at 7:02 AM
The first project aims to identify transcriptomic susceptibilities (in gene expression and alternative #splicing) to cancer across mammals to explain differences in cancer prevalence. We will also investigate cancer type evolution under this transcriptomic prism.

www.evomg-dn.eu/project/evol...
October 15, 2025 at 7:02 AM
Reposted by Manuel Irimia
The second is about potential fitness costs of cancer drug resistance, and how we might exploit them using approaches like adaptive therapy. (building on our work with @mlockley.bsky.social in ovarian cancer: aacrjournals.org/cancerres/ar...). Description here: www.icr.ac.uk/study-and-ca...
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Carboplatin adaptive therapy improves treatment efficacy without increasing daily dose due to reduced fitness of drug-resistant populations, which can be tracked using cfDNA and could direct adaptive ...
aacrjournals.org
October 14, 2025 at 8:26 PM
Reposted by Manuel Irimia
Next, Manuel Irimia ( @mirimiam.bsky.social ), from the EvoMG Program, @melisupf.bsky.social and @crg.eu, presented two recently started projects leveraging comparative transcriptomics to better understand disease.
October 12, 2025 at 2:08 PM